CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation

2000 • 2,211 citations

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

1995 • 2,090 citations

B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes

2000 • 2,090 citations

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

2003 • 1,564 citations

Cancer/testis antigens, gametogenesis and cancer

2005 • 1,541 citations

T-cell quality in memory and protection: implications for vaccine design

2008 • 1,499 citations

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

1999 • 1,000 citations

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

2003 • 981 citations

CTLA-4 ligation blocks CD28-dependent T cell activation.

1996 • 787 citations

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 • 639 citations

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

2007 • 612 citations

Checkpoint Blockade in Cancer Immunotherapy

2006 • 558 citations

CTLA-4 blockade increases IFNγ-producing CD4 ⁺ ICOS ^hi cells to shift the ratio of effector to regulatory T cells in cancer patients

2008 • 498 citations

Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses

2007 • 487 citations

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

2004 • 446 citations

CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation

1999 • 412 citations

CTLA-4: a negative regulator of autoimmune disease.

1996 • 382 citations

NY‐ESO‐1: Review of an Immunogenic Tumor Antigen

2006 • 354 citations

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

2001 • 351 citations

Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade

2005 • 331 citations

Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine

2001 • 307 citations

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

2008 • 244 citations

Polyfunctional T cell responses are a hallmark of HIV‐2 infection

2008 • 235 citations

Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage

2006 • 229 citations

Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer

2007 • 158 citations

T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

2007 • 125 citations

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

2008 • 79 citations

Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients

2007 • 75 citations

Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma

2005 • 65 citations

Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient

2008 • 42 citations

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

2008 • 36 citations

Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen

2006 • 18 citations

Cited By (0)

No citing papers found in database